3 results
Primary: To determine the safety and tolerability of CK3773274 in patients with symptomatic HCMSecondary: Assess long-term effects of CK3773274 on left ventricular outflow tract gradient (LVOT-G) in patients with oHCM
Primary• To evaluate the effect of CK-3773274 on exercise capacity (VO2) in patients with symptomatic oHCMSecondary• To evaluate the effect of CK-3773274 on patient health status• To evaluate the effect of CK-3773274 on New York Heart Association (…
PRIMARY: Dose finding part (Phase 1):To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the recommended Phase 2 doses (RP2Ds) of each…